Recombinant
RabMAb

Recombinant Anti-PDGFR beta (phospho Y1021) antibody [EPR2476] (ab134048)

Overview

  • Product name

    Anti-PDGFR beta (phospho Y1021) antibody [EPR2476]
    See all PDGFR beta primary antibodies
  • Description

    Rabbit monoclonal [EPR2476] to PDGFR beta (phospho Y1021)
  • Host species

    Rabbit
  • Specificity

    Only detects PDGFR beta phosphorylated at tyrosine 1021.

  • Tested applications

    Suitable for: WB, IP, Flow Cyt, Dot blotmore details
    Unsuitable for: ICC or IHC-P
  • Species reactivity

    Reacts with: Mouse
  • Immunogen

    corresponding to Human PDGFR beta.

  • Positive control

    • NIH/3T3 lysates treated with Pervanadate
  • General notes

    Human, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab134048 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/50000 - 1/200000. Predicted molecular weight: 190 kDa.
IP 1/10 - 1/100.
Flow Cyt 1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

 

Dot blot 1/1000.
  • Application notes
    Is unsuitable for ICC or IHC-P.
  • Target

    • Function

      Receptor that binds specifically to PDGFB and PDGFD and has a tyrosine-protein kinase activity. Phosphorylates Tyr residues at the C-terminus of PTPN11 creating a binding site for the SH2 domain of GRB2.
    • Involvement in disease

      Note=A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).
      Note=A chromosomal aberration involving PDGFRB may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with TRIP11. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia.
      Note=A chromosomal aberration involving PDGFRB may be a cause of juvenile myelomonocytic leukemia. Translocation t(5;17)(q33;p11.2) with SPECC1.
      Defects in PDGFRB are a cause of myeloproliferative disorder chronic with eosinophilia (MPE) [MIM:131440]. A hematologic disorder characterized by malignant eosinophils proliferation. Note=A chromosomal aberration involving PDGFRB is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein.
      Note=A chromosomal aberration involving PDGFRB may be the cause of a myeloproliferative disorder (MBD) associated with eosinophilia. Translocation t(1;5)(q23;q33) that forms a PDE4DIP-PDGFRB fusion protein.
    • Sequence similarities

      Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
      Contains 5 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications

      Autophosphorylated. Dephosphorylated by PTPRJ at Tyr-751, Tyr-857, Tyr-1009 and Tyr-1021.
    • Cellular localization

      Membrane.
    • Information by UniProt
    • Database links

    • Alternative names

      • Beta platelet derived growth factor receptor antibody
      • Beta-type platelet-derived growth factor receptor antibody
      • CD 140B antibody
      • CD140 antigen-like family member B antibody
      • CD140b antibody
      • CD140b antigen antibody
      • IBGC4 antibody
      • IMF1 antibody
      • JTK12 antibody
      • OTTHUMP00000160528 antibody
      • PDGF R beta antibody
      • PDGF Receptor beta antibody
      • PDGF-R-beta antibody
      • PDGFR 1 antibody
      • PDGFR antibody
      • PDGFR beta antibody
      • PDGFR1 antibody
      • PDGFRB antibody
      • PGFRB_HUMAN antibody
      • Platelet derived growth factor receptor 1 antibody
      • Platelet derived growth factor receptor beta antibody
      • Platelet derived growth factor receptor beta polypeptide antibody
      see all

    Images

    • All lanes : Anti-PDGFR beta (phospho Y1021) antibody [EPR2476] (ab134048) at 1/5000 dilution (Purified)

      Lane 1 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate
      Lane 2 : NIH/3T3 treated with 1mM pervanadate for 30 minutes whole cell lysate
      Lane 3 : NIH/3T3 treated with 1mM pervanadate for 30 minutes whole cell lysate. Then the membrane was incubated with alkaline phosphatase

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

      Predicted band size: 190 kDa



      Blocking/Diluting Buffer and concentration 5% NFDM/TBST

    • Dot blot analysis of PDGFR beta (phospho Y1021) phospho peptide (Lane 1) and PDGFR beta non-phospho peptide (Lane 2) labeling PDGFR beta (phospho Y1021) phospho peptide with ab134048 at a dilution of 1/1000 dilution (0.54ug/ml). A Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) was used as the secondary antibody at a dilution of 1/20,000 dilution.

      Blocking buffer: 5% NFDM/TBST. Dilution buffer: 5% NFDM /TBST .

    • All lanes : Anti-PDGFR beta (phospho Y1021) antibody [EPR2476] (ab134048) at 1/50000 dilution

      Lane 1 : NIH/3T3 untreated
      Lane 2 : NIH/3T3 treated with Pervanadate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution

      Predicted band size: 190 kDa

    References

    ab134048 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Application
    Western blot
    Sample
    Human Cell lysate - whole cell (Human cancer cell lines)
    Gel Running Conditions
    Reduced Denaturing (4-15% gradient)
    Loading amount
    30 µg
    Treatment
    Activated with PDGF-BB protein
    Specification
    Human cancer cell lines
    Blocking step
    BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C

    Prashant Thakkar

    Verified customer

    Submitted Aug 22 2017

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up